The University of Southampton
University of Southampton Institutional Repository

Room for improvement in the pharmacological treatment of anxiety disorders

Room for improvement in the pharmacological treatment of anxiety disorders
Room for improvement in the pharmacological treatment of anxiety disorders
Anxiety disorders are common in community settings and in primary and secondary medical care. The associated societal burden is considerable, but many of those who might benefit from pharmacological or psychological treatment are not recognised or treated. By contrast, some patients receive unnecessary or inappropriate interventions. Recent evidence-based guidelines for pharmacological management of patients with anxiety disorders recommend initial treatment with either a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. However, there is considerable room for improvement in both the efficacy and tolerability of pharmacological treatment. For example, response rates to initial treatment can be disappointing and it is still not possible to predict reliably which patients will respond well and which will show only a limited response to treatment. Furthermore, many patients fear or experience unwanted and distressing adverse effects and this limits the effectiveness of pharmacological treatments in clinical practice. Because of the relative lack of longitudinal studies of clinical outcomes in anxiety disorders and the small number of placebo-controlled relapse prevention studies, the optimal duration of treatment after a satisfactory response to acute treatment is still uncertain. There have been comparatively few studies of the further management of patients who do not respond to initial treatment and there is a clear need for further randomised controlled trials of augmentation treatment, in patients who do not respond to a selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor or other initial pharmacological approaches. Future treatment guidelines will be influenced by emerging data with both established and novel pharmacological interventions and through better identification of patient sub-groups that are likely to respond preferentially to particular interventions
therapeutic use, clinical trials as topic, longitudinal studies, fear, adverse effects, anxiety disorders, drug therapy, serotonin uptake inhibitors, humans
3482-3491
Baldwin, D. S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Baldwin, D. S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e

Baldwin, D. S. (2008) Room for improvement in the pharmacological treatment of anxiety disorders. Current Pharmaceutical Design, 14 (33), 3482-3491. (doi:10.2174/138161208786848810).

Record type: Article

Abstract

Anxiety disorders are common in community settings and in primary and secondary medical care. The associated societal burden is considerable, but many of those who might benefit from pharmacological or psychological treatment are not recognised or treated. By contrast, some patients receive unnecessary or inappropriate interventions. Recent evidence-based guidelines for pharmacological management of patients with anxiety disorders recommend initial treatment with either a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. However, there is considerable room for improvement in both the efficacy and tolerability of pharmacological treatment. For example, response rates to initial treatment can be disappointing and it is still not possible to predict reliably which patients will respond well and which will show only a limited response to treatment. Furthermore, many patients fear or experience unwanted and distressing adverse effects and this limits the effectiveness of pharmacological treatments in clinical practice. Because of the relative lack of longitudinal studies of clinical outcomes in anxiety disorders and the small number of placebo-controlled relapse prevention studies, the optimal duration of treatment after a satisfactory response to acute treatment is still uncertain. There have been comparatively few studies of the further management of patients who do not respond to initial treatment and there is a clear need for further randomised controlled trials of augmentation treatment, in patients who do not respond to a selective serotonin reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor or other initial pharmacological approaches. Future treatment guidelines will be influenced by emerging data with both established and novel pharmacological interventions and through better identification of patient sub-groups that are likely to respond preferentially to particular interventions

Full text not available from this repository.

More information

Published date: November 2008
Keywords: therapeutic use, clinical trials as topic, longitudinal studies, fear, adverse effects, anxiety disorders, drug therapy, serotonin uptake inhibitors, humans

Identifiers

Local EPrints ID: 70078
URI: https://eprints.soton.ac.uk/id/eprint/70078
PURE UUID: 7b002d5a-b98a-4ab3-a1cc-acfda65e7fd0

Catalogue record

Date deposited: 21 Jan 2010
Last modified: 19 Jul 2017 00:04

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×